Hepatic Encephalopathy. Hepatic failure,not elsewhere classified
Conditions
Interventions
Intervention 1: Intervention Group :1 – Lactulose: Oral lactulose, 45–90 mL three times daily for 14 days. Intervention 2: Intervention group: 2 – Polyethylene Glycol (PEG): Oral PEG, 30–60 g three ti
Sponsors
Boushehr University of Medical Sciences
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: Age 18 years or older Diagnosis of liver cirrhosis based on clinical, laboratory, and imaging criteria Hepatic encephalopathy grade I to IV according to the West-Haven criteria
Exclusion criteria
Exclusion criteria: Lack of consent to participate in the study History of allergy to lactulose or PEG Presence of other liver diseases such as acute viral hepatitis or primary biliary cholangitis Severe liver failure (Child-Pugh C) Active gastrointestinal bleeding
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Hepatic encephalopathy severity using HESA. Timepoint: Daily (14 days). Method of measurement: Daily assessment by physician or nurse.;In-hospital mortality/Alive or deceased status during hospitalization. Timepoint: Until discharge. Method of measurement: record from patient medical record. | — |
Secondary
| Measure | Time frame |
|---|---|
| In hospital mortality. Timepoint: At the end of hospitalization. Method of measurement: In-hospital mortality is recorded in the patient’s medical record by the attending physician, including the date and cause of death.;Length of hospital stay (day). Timepoint: At discharge or death. Method of measurement: Outcome Measurement Method: Calculated as the difference between discharge and admission dates and recorded in the patient’s medical record.;Lenght of ICU stay (days). Timepoint: At discharge or death. Method of measurement: Calculated from ICU admission and discharge dates and recorded in the patient’s medical record.;Requirment for ICU admission (yes/no). Timepoint: Assessed at any time during hospitalization. Method of measurement: Recorded in the patients medical record if transferred to ICU.;Drug related adverse events(type and severity). Timepoint: Monitored daily during hospitalization. Method of measurement: Monitored daily by the medical team and recorded with type and severity in the patients medical record. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactBijan Vaziri
Boushehr University of Medical Sciences
Outcome results
None listed